Thalia Therapeutics: The Drug Could Work

Thalia Therapeutics (LSE:THAT) has signed a Clinical Trial Agreement, a decisive step forward in advancing a treatment for Leukaemia. The Company is developing innovative RNA-based therapeutics and delivery technologies across oncology and cardiovascular disease. An agreement with City of Hope, one of the world's leading cancers research and treatment centres supports completion of Phase 1 trial in Acute Myeloid Leukaemia (AML).The ongoing study is designed to assess the safety and tolerability of miRisten and explore initial signs of efficacy. An interim readout is expected in the last quarte...